Biomea Fusion, Inc.

What they do

Biomea is developing icovamenib, an oral covalent menin inhibitor, in type 1 and type 2 diabetes, and BMF-650, an oral GLP-1 receptor agonist, for obesity. The company has approximately 40 employees following a 2025 strategic realignment and has discontinued its oncology studies of icovamenib. It has not generated any revenue from product sales and funds operations through equity capital raises.

Revenue drivers

• Product revenue — None. The company states it has never generated revenue from product sales and does not expect to unless a product candidate is approved and commercialized.
• Icovamenib (menin inhibitor) — Lead clinical program; no revenue. Being evaluated in two Phase II type 2 diabetes trials (COVALENT-211 and COVALENT-212), with topline 26-week data expected in the fourth quarter of 2026.
• BMF-650 (oral GLP-1 RA) — Obesity candidate; no revenue. Phase I GLP-131 trial in obese, otherwise healthy volunteers is ongoing, with topline results expected in the third quarter of 2026.
• BMF-500 (FLT3 inhibitor) — Oncology asset; no revenue. Internal development was discontinued and the company plans to explore partnerships to advance it.

Recent performance

Biomea reported no revenue and a net loss of $20.7 million for the six months ended June 30, 2026, versus a $50.0 million net loss for the same period in 2025. Full-year 2025 net loss was $61.8 million, down from $138.4 million in 2024, with operating cash use of $70.4 million in 2025 versus $119.9 million in 2024. As of June 30, 2026, the company had $34.8 million in cash and equivalents, $36.9 million in total assets, $24.7 million in total liabilities, and $12.1 million in shareholder equity.

Strategy

Biomea is concentrating resources on metabolic disease after discontinuing icovamenib oncology studies and seeking partners for BMF-500. It completed chronic toxicology studies for icovamenib in two species, supporting dosing beyond the 12-week duration used to date. The company has initiated the Phase II COVALENT-211 and COVALENT-212 trials of icovamenib in type 2 diabetes and is running the Phase I GLP-131 trial of BMF-650. It also plans an investigator-sponsored Phase II trial in recently diagnosed type 1 diabetes with four U.S. academic centers, expected to start in the second half of the year. Management emphasizes capital efficiency and a streamlined operating structure.

Risks

• Limited cash runway — Management states existing cash and restricted cash at June 30, 2026, without future financing, will only fund operations into the second quarter of 2027.
• No approved products or revenue — The company has never generated product revenue, has not completed clinical development of any candidate, and may never commercialize a product.
• Clinical and regulatory uncertainty — Icovamenib and BMF-650 remain in Phase II and Phase I testing respectively, and the company has limited experience conducting clinical trials.
• Accumulated deficit — As of June 30, 2026, accumulated deficit was $469.8 million, and the company expects to continue incurring significant operating losses.

Outlook

Management expects topline 26-week data from the Phase II COVALENT-211 and COVALENT-212 type 2 diabetes trials in the fourth quarter of 2026 and topline results from the Phase I GLP-131 obesity trial in the third quarter of 2026. It plans to initiate an investigator-sponsored Phase II type 1 diabetes trial with four U.S. academic centers in the second half of the year. The company projects its cash runway into the second quarter of 2027 and expects to continue incurring significant losses.